ArticleJournal of clinical laboratory analysis2018
High mobility group box 1 as a biomarker in critically ill patients.
Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Macrophage metabolism reprogramming in sepsis: Pathogenesis and therapeutic implications (Review).International journal of molecular medicine · 2026Review
- Review
- Post-translational modifications in sepsis-induced organ dysfunction: mechanisms and implications.Frontiers in immunology · 2024Review
- HMGB1 lactylation drives neutrophil extracellular trap formation in lactate-induced acute kidney injury.Frontiers in immunology · 2024Article
- Effect of HMGB1 and HBD-3 levels in the diagnosis of sepsis- A comparative descriptive study.Biochemistry and biophysics reports · 2023Article
- Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis.Cell death and differentiation · 2022Article
- A Porcine Sepsis Model With Numerical Scoring for Early Prediction of Severity.Frontiers in medicine · 2022Article
- High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as Biomarkers in Critically Ill COVID-19 Patients.The American journal of tropical medicine and hygiene · 2021Article
- Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis.Nature communications · 2021Article
- The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility.Translational research : the journal of laboratory and clinical medicine · 2020Review
- The exogenous delivery of microRNA-449b-5p using spermidine-PLGA nanoparticles efficiently decreases hepatic injury.RSC advances · 2019Article
- Response to the "Letter to the editor regarding article, 'High-mobility group box 1 as a biomarker in critically ill patients'."Journal of clinical laboratory analysis · 2019Article
- Letter to the Editor Regarding Article, "High mobility group box 1 as a biomarker in critically ill patients".Journal of clinical laboratory analysis · 2019Article
- High mobility group box 1 as a biomarker in critically ill patients.Journal of clinical laboratory analysis · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundExtracellular release of high mobility group box 1 (HMGB1) acts as a danger-associated molecular pattern, thereby "alarming" the immune system and promoting systemic inflammation. We investigated plasma HMGB1 concentrations as a potential diagnostic and prognostic biomarker in critical illness.
methodsOur study included 218 critically ill patients (145 with sepsis, 73 without sepsis), of whom blood samples were obtained at the time-point of admission to the medical intensive care unit (ICU).
resultsHigh mobility group box 1 levels were significantly elevated in critically ill patients (n = 218) compared with healthy controls (n = 66). Elevated HMGB1 plasma levels were independent from the presence of sepsis. Moreover, HMGB1 was not associated with disease severity, organ failure, or mortality in the ICU. We observed a trend toward lower HMGB1 levels in ICU patients with pre-existing obesity, type 2 diabetes and end-stage renal disease patients on chronic hemodialysis.
conclusionIn conclusion, our study did not reveal significant associations between HMGB1 levels at ICU admission and clinical outcomes in critically ill patients. Due to the pathogenic role of HMGB1 in the late phases of experimental sepsis, future studies might assess the potential value of HMGB1 by measuring its plasma concentrations at later time points during the course of critical illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.